Article Details
Retrieved on: 2023-09-11 11:41:37
Tags for this article:
Click the tags to see associated articles and topics
Excerpt
VYD222 is a broadly neutralizing, half-life extended monoclonal antibody (mAb) candidate in development for the prevention of symptomatic COVID-19 ...
Article found on: www.globenewswire.com
This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.
Sign UpAlready have an account? Log in here